Lexaria Bioscience Corp.
LEXX
$1.35
-$0.34-20.12%
NASDAQ
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 525.90K | 496.90K | 464.30K | 411.00K | 404.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 525.90K | 496.90K | 464.30K | 411.00K | 404.70K |
| Cost of Revenue | 2.70K | 2.70K | 4.80K | 4.80K | 17.50K |
| Gross Profit | 523.20K | 494.20K | 459.50K | 406.20K | 387.20K |
| SG&A Expenses | 4.67M | 4.00M | 3.79M | 3.07M | 2.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.86M | 7.74M | 6.16M | 4.97M | 5.62M |
| Operating Income | -9.33M | -7.25M | -5.70M | -4.56M | -5.22M |
| Income Before Tax | -9.39M | -7.33M | -5.81M | -4.87M | -5.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.39 | -7.33 | -5.81 | -4.87 | -5.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 11.10K | 10.50K | 13.30K | 21.20K | 30.70K |
| Net Income | -9.38M | -7.32M | -5.80M | -4.85M | -5.44M |
| EBIT | -9.33M | -7.25M | -5.70M | -4.56M | -5.22M |
| EBITDA | -9.26M | -7.17M | -5.62M | -4.43M | -5.07M |
| EPS Basic | -0.58 | -0.49 | -0.46 | -0.47 | -0.71 |
| Normalized Basic EPS | -0.36 | -0.30 | -0.28 | -0.27 | -0.42 |
| EPS Diluted | -0.58 | -0.49 | -0.46 | -0.47 | -0.71 |
| Normalized Diluted EPS | -0.36 | -0.30 | -0.28 | -0.27 | -0.42 |
| Average Basic Shares Outstanding | 63.75M | 57.00M | 49.38M | 41.78M | 34.37M |
| Average Diluted Shares Outstanding | 63.75M | 57.00M | 49.38M | 41.78M | 34.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |